17.15
-5.77%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Guilin Sanjin Pharmaceutical Co
Its shares trade on Shenzhen under the ticker 002275.SZ. It has been listed since 10 July 2009. In the fiscal year to 31 December 2025, it reported revenue of CN¥2.05bn and net income of CN¥433.1m. At that date it held total assets of CN¥4.26bn and shareholders' equity of CN¥3.19bn.
Guilin Sanjin Pharmaceutical Co., Ltd. engages in the research and production of traditional Chinese and Natural medicine. The company is headquartered in Guilin, Guangxi. The company went IPO on 2009-07-10. The firm's main products portfolio consists of watermelon frost series, including watermelon frost lozenge, guilin watermelon frost and watermelon frost throat lozenge, mainly used for treatment of throat and mouth diseases; sanjin tablets, mainly used for treatment of urinary system infection, as well as naomaitai capsules, mainly used for treatment of cardiovascular and cerebrovascular diseases. The company distributes its products within domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 10 Jul 2009
- Employees
- 2,720
- Website
- sanjin.com.cn ↗
Leadership
Pay as last reported
- Mr. Xun ZouChairman of the Board, President, since 2010CN¥2.4m
- Mr. Yuangang XieFinance Director, Vice President, Director, since 2016CN¥1.3m
- Mr. Jinqian XuChief Human Resource Officer, DirectorCN¥632,000
- Mr. Chun LiVice President, Secretary of the BoardCN¥728,000
- Mr. Jingdu LeiVice President, Director, since 2022CN¥795,400
- Mr. Zhun ZouVice President, Director, since 2013CN¥1.2m
- Ms. Liping FuDirectorCN¥642,700
- Mr. Liwen HeIndependent DirectorCN¥80,000
- Mr. Huanfeng LiuIndependent DirectorCN¥40,000
- Ms. Lingxia MoIndependent Director, since 2019CN¥80,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Guilin Sanjin Pharmaceutical employs 2720 employees in Guilin, CN.
- Watermelon frost series treats throat and mouth diseases effectively.
- Sanjin tablets target urinary system infections with strong market presence.
Weaknesses
- Guilin Sanjin's products are limited to domestic and overseas markets only.
- The company has no presence in the Information Technology sector.
- Guilin Sanjin lacks products in the Financials industry.
Opportunities
- Guilin Sanjin can expand its watermelon frost series into new markets.
- The cardiovascular and cerebrovascular market offers growth for naomaitai capsules.
- Guilin Sanjin can leverage its traditional Chinese medicine expertise.
Threats
- Guilin Sanjin faces competition from other Health Care companies in CN.
- The pharmaceutical industry in CN has strict regulatory requirements.
- Guilin Sanjin must comply with international standards for overseas markets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.